|
CORMEDIX Inc. (CRMD) DCF تقييم |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
CorMedix Inc. (CRMD) Bundle
اكتشف الإمكانات الحقيقية لـ Cormedix Inc. (CRMD) مع حاسبة DCF المتقدمة! اضبط الافتراضات الأساسية واستكشاف السيناريوهات المختلفة وتقييم كيفية تأثير التغييرات على تقييم Cormedix Inc. (CRMD) - كل ذلك ضمن قالب Excel واحد.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .2 | .2 | .1 | .0 | 43.5 | 23.3 | 12.5 | 6.7 | 3.6 | 1.9 |
| Revenue Growth, % | 0 | -20.19 | -65.74 | -100 | 0 | -46.48 | -46.48 | -46.48 | -46.48 | -46.48 |
| EBITDA | -27.0 | -29.4 | -30.1 | -48.9 | -22,356.4 | -14.0 | -7.5 | -4.0 | -2.1 | -1.1 |
| EBITDA, % | -11294.67 | -15385.1 | -45945.1 | 100 | -51426.9 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .1 | .2 | .2 | .1 | -22,337.1 | 11.8 | 6.3 | 3.4 | 1.8 | 1.0 |
| Depreciation, % | 59.98 | 92.71 | 319.59 | 100 | -51382.53 | 50.54 | 50.54 | 50.54 | 50.54 | 50.54 |
| EBIT | -27.2 | -29.6 | -30.3 | -49.0 | -19.3 | -11.4 | -6.1 | -3.3 | -1.7 | -.9 |
| EBIT, % | -11354.65 | -15477.81 | -46264.7 | 100 | -44.37 | -48.87 | -48.87 | -48.87 | -48.87 | -48.87 |
| Total Cash | 46.5 | 65.7 | 59.0 | 76.0 | 51,687.6 | 23.3 | 12.5 | 6.7 | 3.6 | 1.9 |
| Total Cash, percent | .0 | .0 | .1 | .0 | .1 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | 51,653.6 | 10.5 | 5.6 | 3.0 | 1.6 | .9 |
| Account Receivables, % | 1.4 | 23.76 | 0 | 100 | 118819.89 | 45.03 | 45.03 | 45.03 | 45.03 | 45.03 |
| Inventories | .1 | .0 | .0 | 2.1 | 7,599.5 | 12.2 | 6.5 | 3.5 | 1.9 | 1.0 |
| Inventories, % | 60.01 | 1.58 | 0 | 100 | 17481.38 | 52.32 | 52.32 | 52.32 | 52.32 | 52.32 |
| Accounts Payable | 1.1 | 2.2 | 2.2 | 4.3 | 1.7 | 18.8 | 10.1 | 5.4 | 2.9 | 1.5 |
| Accounts Payable, % | 471.55 | 1157.22 | 3366.79 | 100 | 3.96 | 80.79 | 80.79 | 80.79 | 80.79 | 80.79 |
| Capital Expenditure | -.1 | -1.4 | -.2 | -.3 | .0 | -11.5 | -6.2 | -3.3 | -1.8 | -.9 |
| Capital Expenditure, % | -47.08 | -746.5 | -335.37 | 100 | 0 | -49.42 | -49.42 | -49.42 | -49.42 | -49.42 |
| Tax Rate, % | 99.91 | 99.91 | 99.91 | 99.91 | 99.91 | 99.91 | 99.91 | 99.91 | 99.91 | 99.91 |
| EBITAT | -22.0 | -28.3 | -29.7 | -49.0 | .0 | -8.5 | -4.6 | -2.4 | -1.3 | -.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -21.0 | -28.4 | -29.6 | -49.2 | -81,590.7 | 59,239.3 | -2.6 | -1.4 | -.8 | -.4 |
| WACC, % | 11.53 | 11.54 | 11.54 | 11.54 | 11.53 | 11.53 | 11.53 | 11.53 | 11.53 | 11.53 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 53,109.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -4 | |||||||||
| Present Terminal Value | -3 | |||||||||
| Enterprise Value | 53,107 | |||||||||
| Net Debt | -40 | |||||||||
| Equity Value | 53,147 | |||||||||
| Diluted Shares Outstanding, MM | 59 | |||||||||
| Equity Value Per Share | 902.76 |
What You Will Receive
- Comprehensive Financial Model: Leverage CorMedix Inc.’s (CRMD) actual data for accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential metrics.
- Real-Time Calculations: Automatic updates provide immediate feedback as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Adaptable and Reusable: Designed for versatility, allowing for repeated applications in detailed forecasting.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for CorMedix Inc. (CRMD).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to CorMedix Inc. (CRMD).
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates as per CorMedix Inc. (CRMD) requirements.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to CorMedix Inc. (CRMD).
- Visual Dashboard and Charts: Graphical representations summarize essential valuation metrics for straightforward analysis of CorMedix Inc. (CRMD).
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered CorMedix Inc. (CRMD) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for CorMedix Inc. (CRMD)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for CorMedix Inc. (CRMD)?
- Designed for Experts: A sophisticated tool tailored for analysts, investors, and healthcare consultants.
- Accurate Data: CorMedix’s historical and projected financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Instantly calculates intrinsic value, NPV, and other essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling CorMedix Inc. (CRMD) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to CorMedix Inc. (CRMD).
- Consultants: Deliver professional valuation insights regarding CorMedix Inc. (CRMD) to clients quickly and accurately.
- Business Owners: Understand how companies like CorMedix Inc. (CRMD) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to CorMedix Inc. (CRMD).
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations specific to CorMedix Inc. (CRMD).
- Real-World Data: CorMedix’s historical and projected financials preloaded for analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to test various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for deeper insights into CorMedix Inc. (CRMD).
- Key Ratios: Built-in analysis for profitability, efficiency, and leverage metrics relevant to CorMedix Inc. (CRMD).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results tailored to CorMedix Inc. (CRMD).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.